Basic Information
| LncRNA/CircRNA Name | MEG3 |
| Synonyms | NA |
| Region | GRCh38_14:100779410-100861031 |
| Ensemble | ENSG00000214548 |
| Refseq | NR_002766 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | melanoma |
| ICD-0-3 | NA |
| Methods | RT-PCR, Western blot (WB) analysis, Dual luciferase array |
| Sample | tumor tissues,melanoma cell lines (HEMn, A375 and A2058) and murine melanoma cell lines (B16) |
| Expression Pattern | down-regulated |
| Function Description | lncRNA MEG3 and E-cadherin expressions were both declined in carcinoma tissues as compared with their para-carcinoma tissues. lncRNA MEG3 might inhibit the tumor growth, tumor metastasis and formation of melanoma by modulating miR-21/E-cadherin axis. |
| Pubmed ID | 31938020 |
| Year | 2020 |
| Title | LncRNA MEG3 Promotes Melanoma Growth, Metastasis and Formation Through Modulating miR-21/E-cadherin Axis |
External Links
| Links for MEG3 | GenBank HGNC NONCODE |
| Links for melanoma | OMIM COSMIC |